With oncology continuing to bear ripe opportunities for investors, new modalities such as antibody-drug conjugates (ADCs) and radiopharmaceuticals are garnering significant interest. These approaches offer promising therapeutic options for various cancer types, driving advancements in treatment efficacy and improvements in patient outcomes. This session will feature oncology experts who will discuss the latest developments in ADCs and radiopharmaceutical therapies. Attendees will gain insights into the oncology modalities attracting high investor interest, the science behind these therapeutic candidates, and the potential investment opportunities that will be of interest in the near term.​